Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo. Safety will be assessed by incidences of treatment-emergent adverse events, treatment-emergent serious adverse events, injection site reactions and other adverse events of special interest, and the clinically significant laboratory values after injections of Engensis compared to Placebo. Exploratory endpoints include assessment of muscle function using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale subscores for Fine and Gross Motor Function; muscle strength by quantitative testing using handheld dynamometry and the Accurate Test of Limb Isometric Strength where available; quality of life using the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40; patient global impression of change, clinical global impression of change, and clinical global impression of severity; and evaluation of lung function using Slow Vital Capacity. Muscle biopsies will be performed during the study for future biomarker analyses.

Key facts

Study ID: NCT04632225
Run by: Helixmith Co., Ltd.
People needed: 18
Starts: 2021-03-09
Expected to finish: 2024-07-15
Last updated by the study team: 2025-10-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Clinically definite or probable Amyotrophic Lateral Sclerosis or laboratory-supported probable Amyotrophic Lateral Sclerosis as defined in the revised El Escorial/Airlie House diagnostic criteria
The site of onset of Amyotrophic Lateral Sclerosis symptoms is a limb and experiencing symptoms of lower motor dysfunction (e.g., weakness, atrophy, cramps, poor circulation, etc.) with upper motor neuron symptoms (e.g., weakness, brisk reflexes, spasticity)
Onset of Amyotrophic Lateral Sclerosis symptoms ≤ 4 years
Slow Vital Capacity ≥ 50% of predicted value at Screening
Not taking riluzole, or on a stable dose (defined as no noted toxicities) for at least 30 days prior to Screening and throughout the study
Not taking edaravone or on a maintenance cycle for at least 30 days prior to Screening and throughout the study
For females of childbearing potential, a negative urine pregnancy test at Screening and on Day 0
Male Participants and their female partners must agree to use double-barrier contraception during the study or provide proof of postmenopausal state (minimum 1 year) or surgical sterility
Male Participants must not donate sperm during the study
Female Participants must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, or surgically sterile for at least 3 months, or agree to use double-barrier contraception from 28 days prior to randomization (Day 0) and/or their last confirmed menstrual period prior to study randomization (whichever is longer) until the end of the study
Capable of complying and willing to comply with the requirements and restrictions in the informed consent form and this protocol
Willing to forgo new experimental Amyotrophic Lateral Sclerosis treatments for at least 6 months following randomization

You may not qualify if…

Progressive or degenerative neurological disorder such as Alzheimer's disease, Parkinson's disease, vascular dementia, multiple sclerosis, and other neurological or vascular disorders felt by the Investigator to preclude participation
Requires tracheotomy ventilation or noninvasive ventilation related to bulbar function
Evidence by physical examination, history, or laboratory evaluation of significant concomitant disease with a life expectancy of < 6 months at Screening
International Normalized Ratio values >2.0
Platelet count <100,000/µL
Inflammatory disorder of the blood vessels (inflammatory angiopathy or vasculitis, such as Buerger's disease)
Active infection (chronic infection or severe active infection that may compromise the Participant's wellbeing or participation in the study in the Investigator's judgment)
Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)
Positive human immunodeficiency virus or human T-cell lymphotrophic virus I/II test at Screening
Active acute or chronic hepatitis B
Active hepatitis C
Immunosuppression due to underlying disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) or to currently receiving immunosuppressive drugs, (e.g., chemotherapy, corticosteroids) or to radiation therapy
Stroke or myocardial infarction within 3 months prior to Screening
Active deep vein thrombosis
Recent history (< 3 years) or presence of cancer except basal cell carcinoma or squamous cell carcinoma of the skin that was excised and has shown no evidence of recurrence for at least 1 year
Major psychiatric disorder diagnosed in the past 6 months that has not been stabilized or in the Investigator's opinion would not allow the patient to participate in the scheduled procedures
Use of an investigational drug for the treatment of Amyotrophic Lateral Sclerosis in the past 30 days or 5 half-lives (if available), whichever is longer, or previous participation in a clinical study with Engensis
Stem cell administration for investigational treatment of Amyotrophic Lateral Sclerosis or other conditions in the 6 months prior to Screening

Where it is running

St. Joseph's Hospital and Medical Center, Barrows Neurological Institute — Phoenix, Arizona, United States
Northwestern University — Chicago, Illinois, United States
Johns Hopkins University Department of Neurology — Baltimore, Maryland, United States
Austin Neuromuscular Center — Austin, Texas, United States
Hanyang University Medical Center — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.